Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Novel assembloid illuminates serotonin changes linked to 22q11.2 deletion
The combination of a serotonin-producing organoid with an organoid based on the developing cerebral cortex offers a new way to investigate neuromodulation.
Novel assembloid illuminates serotonin changes linked to 22q11.2 deletion
The combination of a serotonin-producing organoid with an organoid based on the developing cerebral cortex offers a new way to investigate neuromodulation.
Reporter’s notebook: Highlights from INSAR 2026
At the 25th annual meeting of the International Society for Autism Research, scientists, clinicians and self-advocates gathered to discuss topics such as autism genetics and the gap between clinical trials and real-world benefits.
Reporter’s notebook: Highlights from INSAR 2026
At the 25th annual meeting of the International Society for Autism Research, scientists, clinicians and self-advocates gathered to discuss topics such as autism genetics and the gap between clinical trials and real-world benefits.
Scientists push back against stricter European Research Council grant application rules
In an open letter, scientists call the ERC’s suggestion to block grant reapplications for an additional year “at odds with scientific excellence.”
Scientists push back against stricter European Research Council grant application rules
In an open letter, scientists call the ERC’s suggestion to block grant reapplications for an additional year “at odds with scientific excellence.”